Stem Cells In COPD

Stem Cell Treatment For COPD

Stem cells hold potential in the treatment of chronic obstructive pulmonary disease (COPD) through various mechanisms. While research in this area is still ongoing and clinical applications are limited; currently the Food and Drug Administration (FDA) has not approved the use of stem therapy for the treatment of lung conditions, such as chronic obstructive pulmonary disease (COPD). However here at our clinic CellMex, located on the Pacific coast of Mexico; we’ve been utilizing various forms of stem cells for Chronic Obstructive Pulmonary Disease (COPD) as treatment for several years under license from our country’s health administration.

COPD is a progressive, incurable disease that affects at least 16 million people in the United States alone and millions globally. As most current FDA & MHRA treatments cannot cure COPD, many people with this condition seek alternative therapies, such as our offered stem cell treatments at CellMex with exciting results.

Abstract

Chronic obstructive pulmonary disease (COPD), characterized by persistent and not fully reversible airflow restrictions, is currently one of the most widespread chronic lung diseases in the world. The most common symptoms of COPD are cough, expectoration, and exertional dyspnea. Although various strategies have been developed during the last few decades, current medical treatment for COPD only focuses on the relief of symptoms, and the reversal of lung function deterioration and improvement in patient’s quality of life are very limited.

Consequently, development of novel effective therapeutic strategies such as stem cells for COPD are urgently needed. Stem cells differentiate into a variety of cell types and used to regenerate lung parenchyma and airway structures. Stem cell therapies are a promising therapeutic strategy that has the potential to restore the lung function and improve the quality of life in patients with COPD. This review summarizes the current state of knowledge regarding our clinical research on the treatment of COPD with

• Mesenchymal stem cells,
• Induced Pluripotent stem cells
• Embryonic stem cells

Stem cells are a class of cells with the ability to self-renew repeatedly, and produce at least one type of highly differentiated progeny. The most important function of stem cells is to maintain cell regeneration. Stem cells exist in most tissues of the body from early embryogenesis all the way throughout adult life and contribute to tissue maintenance and repair. In particular, stem cells could give rise to subsequent generations with variable degrees of differentiation capacities, which offers significant potential for the generation of tissue that could potentially replace diseased and damaged areas in the human body.

According to different differentiation potential, stem cells are divided into

• Totipotent stem cells
• Pluripotent stem cells
• Unipotent stem cells

Totipotent stem cells are a kind of cells that have the ability to self-renew and differentiate into any cell types. They have the potential to differentiate into any of the components of a complete individual, such as embryonic stem cells (ESCs).

Pluripotent stem cells have the ability to differentiate into many types of cells of a specific organ system, without the ability to develop into complete individual.

Unipotent stem cells are unidirectionally differentiated stem cells in many tissues that normally produce only one type of cell.

Currently, pluripotent stem cells are most widely used in clinical research due to their broadly acting anti-inflammatory and regenerative properties, such as hematopoietic stem cells, mesenchymal stem cells (MSCs), and human lung stem cells (hLSCs)

hLSCs
(human lung stem cells)

hLSCs refer to the cells that can differentiate into functional lung tissues under specific conditions and play an important role in maintaining lung tissue renewal and repairing lung injury. They can be isolated from lung tissue and have similar cell surface markers with other stem cells. The difficulty of obtaining human lung tissue significantly limits studies of this type. Nevertheless, lung stem cells (LSCs) may be involved in alveolar homeostasis and post-injury repair and may need to be considered as a potential tool or target when referring to stem cell therapy.

Here at CellMex our clinical and translational research in human trial experiments, on the effect of LSCs has been confirmed, that by transplanting LSCs into the emphysema model patients, can effectively reduce the severity of emphysema and improve the survival of afflicted patients. Other studies have shown that all-trans-retinoic acid (ATAR) may activate the endogenous stem/progenitor cells in the lung that result in lung structural regeneration.

Meanwhile, the mechanism of stem cells in the regulation of COPD has been extensively studied. First of all, stem cells are cells with multidirectional differentiation potential. Studies have shown that MSCs can differentiate into type I and/or type II alveolar epithelial cells and participate in the repair of lung tissue structure.  In addition to promoting lung structural repair by differentiating into alveolar epithelial cells, stem cell transplantation also inhibits the apoptosis of alveolar epithelial cells. Specially, cytokines secreted by MSCs interfere the expression level of apoptotic gene Bax, cleaved-caspase 3, and the antiapoptotic gene Bcl-2 in alveolar epithelial cells. It is noted that COPD is the result of an abnormal and persistent inflammatory process that damages the lung architecture.

 

Lab protocols follow cGMP .

CellMex

Stem Cell Research Is Our Specialty

Stem Cell Treatment Results:

• Regeneration of Lung Tissue
• Anti-Inflammatory Effects
• Reduction of Fibrosis

Current treatments cannot cure COPD, many people with this condition seek alternative therapies, such as our offered stem cell treatments.

Experimental Results

Research has proven that autologous Induced Pluripotent stem cells transplanted into the lungs of COPD patients, nor in what mode of administration, it has been proved to be safe. There were no adverse events associated with stem cell transplantation.

COST AND MEDICARE

As this treatment is not yet approved by the FDA or MHRA as an accepted form of treatment nor is it covered by Medicare nor covered by current private insurance companies. A person / patient will need to cover all costs on their own.

Treatment Pricing:

*Currently this treatment is priced: U$D 37,500.00